Infliximab Depression Study

Inflammation may contribute to the development of motivational impairments and underlying corticostriatal circuit dysfunction in a subset of patients with major depression, which affects approximately 20 million adults in the US. Through a combination of functional neuroimaging and placebo-controlled inflammation blockade in a sample of depressed patients with high levels of inflammation, this project will determine the extent to which inflammation contributes to motivational symptoms and whether corticostriatal circuit function mediates this relationship. The proposed studies will help validate the immune system and corticostriatal reward circuits as important targets for the development of novel anti-inflammatory treatment and prevention strategies, which in turn can be used to personalize treatments for patients with high inflammation and motivational deficits. Click here to learn more.